HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

BeOne's Brukinsa hits goal in mantle cell lymphoma confirmatory trial

A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a "new chemotherapy-free standard" in first-line mantle cell lymphoma.

By FiercePharma · Jun 30, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Praxis faces FDA decision delay as analysts point finger at agency layoffs
The FDA has delayed a decision on the approval of Praxis Precision Medicine's rare epilepsy prospect by three …
Jun 30, 2026
FDA Updates List of Off-Patent Drugs Without Approved Generics
The WeekBriefing
FDA Updates List of Off-Patent Drugs Without Approved Generics
The FDA’s June 2026 update again highlights brand drugs still lacking generic challengers, aiming to spur ANDA…
Jun 30, 2026
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
The WeekPharmaceutical Technology ↗
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb pro…
Jun 30, 2026